Biomedical Engineering Reference
In-Depth Information
115. Jain L et al (2008) Development of a rapid and sensitive LC-MS/MS assay for the determina-
tion of sorafenib in human plasma. J Pharm Biomed Anal 46:362-367
116. Zhao M et al (2007) A rapid and sensitive method for determination of sorafenib in human
plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B
Analyt Technol Biomed Life Sci 846:1-7
117. Bai F et al (2006) Determination of lapatinib (GW572016) in human plasma by liquid chro-
matography electrospray tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr B
Analyt Technol Biomed Life Sci 831:169-175
118. Bai F et al (2011) Determination of vandetanib in human plasma and cerebrospinal fluid by
liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
J Chromatogr B Analyt Technol Biomed Life Sci 879:2561-2566
119. Lankheet AG et al (2009) A validated assay for the quantitative analysis of vatalanib in
human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem
mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:3625-3630
120. Sparidans RW et al (2009) Liquid chromatography-tandem mass spectrometric assay for the
light sensitive tyrosine kinase inhibitor axitinib in human plasma. J Chromatogr B Analyt
Technol Biomed Life Sci 877:4090-4096
121. Novakova L et al (2006) Advantages of application of UPLC in pharmaceutical analysis.
Talanta 68:908-918
122. Haouala A et al (2009) Therapeutic drug monitoring of the new targeted anticancer agents
imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spec-
trometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:1982-1996
123. Baratte S et al (2004) Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor,
and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrome-
try following semi-automated liquid-liquid extraction. J Chromatogr A 1024:87-94
124. Anja Goedl P. Pfizer, Personal communication. 12 Dec 2007
125. Yamazaki S et al (2011) Prediction of oral pharmacokinetics of cMet kinase inhibitors in
humans: physiologically based pharmacokinetic model versus traditional one-compartment
model. Drug Metab Dispos 39:383-393
126. Christopher LJ et al (2008) Metabolism and disposition of dasatinib after oral administration
to humans. Drug Metab Dispos 36:1357-1364
127. Furlong MT et al (2012) A validated LC-MS/MS assay for the simultaneous determination
of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in
human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal 58:
130-135
128. He K et al (2008) N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical
and practical considerations. J Pharm Sci 97:2568-2580
129. Wu JT et al (2000) Direct plasma sample injection in multiple-component LC-MS-MS assays
for high-throughput pharmacokinetic screening. Anal Chem 72:61-67
130. Hsieh Y et al (2002) Direct cocktail analysis of drug discovery compounds in pooled plasma
samples using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt
Technol Biomed Life Sci 767:353-362
131. Kuo BS et al (1998) Sample pooling to expedite bioanalysis and pharmacokinetic research.
J Pharm Biomed Anal 16:837-846
132. Kummar S et al (2010) Utilizing targeted cancer therapeutic agents in combination: novel
approaches and urgent requirements. Nat Rev Drug Discov 9:843-856
133. De Francia S et al (2009) New HPLC-MS method for the simultaneous quantification of the
antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J Chromatogr B
Analyt Technol Biomed Life Sci 877:1721-1726
134. Demetri GD et al (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in
patients with advanced solid tumors. Clin Cancer Res 15:6232-6240
135. Chahbouni A et al (2009) Simultaneous quantification of erlotinib, gefitinib, and imatinib in
human plasma by liquid chromatography tandem mass spectrometry. Ther Drug Monit 31:
683-687
